London (UK) and Rehovot (Israel) April 24, 2023

Vidac Pharma Holding Plc. (SYM: T9G; ISIN: GB00BM9XQ619; WKN: A3DTUQ). (www.vidacpharma.com)

Vidac Pharma Holding Plc. Informs of automatic expiration of a share purchase facility agreement with General Emerging Market (G.E.M) as for April 13^th, 2023. As financial Planning of the company did not include Proceeds from this Conditional Agreement it is the opinion of the management that this should not affect company activities.

About Vidac Pharma: Vidac Pharma Holding Plc. London, is the holding company of Vidac Pharma Ltd. Rehovot. The Company is a clinical stage biopharmaceutical company dedicated to discovering and developing First-in-class medicines to help people suffering from a range of oncologic and dermatologic diseases.

Disclaimer

The following information does not constitute a public offer to sell or a solicitation to submit an offer to buy or subscribe to shares of Vidac Pharma Holding PLC, but is for informational purposes only.

Vidac Pharma Holding PLC

Dr. Max Herzberg
20-22 Wenlock Road
London N1 7GU
United Kingdom
http://www.vidacpharma.com/
investors@vidacpharma.com
+972-54-4257381
+972 (0)779300647

London (UK) and Rehovot (Israel). VIDAC PHARMA HOLDING PLC (SYM: T9G; ISIN: GB00BM9XQ619; WKN: A3DTUQ). (www.vidacpharma.com) is happy to announce a listing of company shares in the Hamburg Stock Exchange.

Vidac Pharma is a clinical stage company exploiting a new paradigm in Anti-Cancer Drug Discovery by dissociating the enzymatic complex which causes hyper glycolysis in Cancer Cells known as the Nobel Prize winner Warburg Effect. Vidac Pharma is the first company to develop and patent new potent molecules for Cancer treatment based on this basic mechanism which is also used for diagnostic of cancer metastases (PET-Scan) but was reputed as “undruggable” until Vidac Pharma discoveries. Vidac Pharma is in Phase 2 with its proprietary molecules in two Skin Cancer pathologies, cSCC (AK) and CTCL and develops new molecules for solid tumors. 

Vidac Pharma Holding Plc is the Holding Company of Vidac Pharma Ltd from the Weizmann Science Park in Rehovot, Israel.

Disclaimer

The following information does not constitute a public offer to sell or a solicitation to submit an offer to buy or subscribe to shares of Vidac Pharma Holding PLC, but is for informational purposes only.

Vidac Pharma Holding PLC

 Dr. Max Herzberg

  20-22 Wenlock Road

  London N1 7GU

  United Kingdom

http://www.vidacpharma.com/

 investors@vidacpharma.com

 +972-54-4257381

 +972 (0)779300647

Rehovot, Israel Sept 20, 2021

Based of the satisfactory safety data of VIDAC VDA 1102 on selected patients, Vidac Pharma received authorization to widen the scope of the trial to CTCL whole spectrum of conditions.

“We are very satisfied with the results of the first step which on top of the safety results granted to our trial a dose ranging protocol authorization. This will allow us to speed up recruitment at Beilinson Hospital in Israel under the direction of Prof. Emilia Hodak and program a Phase 2B both in Israel and in Europe. In a pre-approval meeting the Austrian Health Authorities (AGES) found our planning satisfactory and recommended such an extension to the full spectrum” declared Dr. Max Herzberg, Vidac Pharma Chairman.

VDA 1102 disrupts the binding of Hexokinase 2 (HK2) which is over expressed in cancer cells and binds to the VDAC channel of mitochondria. This binding causes exagerated glycolysis and blocks apoptosis. The extremely specific displacement of HK2 brings back metabolism to that of a normal cell and corrects tumor microenvironment. The company sees this mechanism of “Toposteric Effect TM” as a novel target to create safer pharmacological entities.

About Vidac:

Vidac Pharma was founded in Israel in 2012 by Dr Max Herzberg and aims to develop anti-cancer drugs based on restoring normal cellular metabolism. Cancer cells are characterized by a high rate of glycolysis and by suppressed apoptosis (programmed death) both of which favorizes high cellular reproduction and Tumor formation.  Vidac’s platform technology restores normal glycolysis and triggers apoptosis in these malignant cells. As normal cells are not subject to overexpression of HK2 they are not affected by Vidac’s drugs. Vidac’s lead drug, VDA-1102, has successfully completed a Phase 2b clinical trial in actinic keratosis (AK) under an IND from the FDA and is presently in a Phase 2a clinical trial in CTCL in Israel. The company’s strategic intellectual property portfolio covers broadly its general approach using the TopostericTM effect avoiding enzymatic cell mis-location.

For Further information about Vidac Pharma:
Max Herzberg, PhD. Active Chairman of the Board 
info@vidacpharma.com  
www.vidacpharma.com

Rehovot, Israel Sept 13, 2021

Vidac Pharma Ltd. announces that it was granted a USA Patent for a new chemical family of compounds targeting the HK2-VDAC system developed by the company. The new compounds are hydrophilic and were developed to fit systemic use such as IV, IM and/or Per-Os use. “This is opening the way to explore possible treatment of solid tumors overexpressing HK2 such as Prostate, Pancreas and other critical Oncological conditions” said Dr Max Herzberg, Chairman of Vidac Pharma “We are now going to fully develop this new product with the aim of a first in man end of 2022”. The new Chemical entities covered by the US Patent have no relation with the VDA 1102 a Clinical stage proprietary molecule currently under Phase 2 for both Actinic Keratosis and Cutaneous T-Cell Lymphoma while working through the same mechanism i.e detachment of HK2 from the VDAC channel in Mitochondria thus stopping the hyper glycolysis characterizing Cancer (Warburg effect) and promoting immunological response of the tumor microenvironment. In view of the novelty of these new chemical entities and their possible use to fight cancer the Company is optimist in receiving worldwide coverage.

About Vidac:

Vidac Pharma was founded in Israel in 2012 by Dr Max Herzberg and aims to develop anti-cancer drugs based on restoring normal cellular metabolism. Cancer cells are characterized by a high rate of glycolysis and by suppressed apoptosis (programmed death) both of which favorizes high cellular reproduction and Tumor formation.  Vidac’s platform technology restores normal glycolysis and triggers apoptosis in these malignant cells. As normal cells are not subject to overexpression of HK2 they are not affected by Vidac’s drugs. Vidac’s lead drug, VDA-1102, has successfully completed a Phase 2b clinical trial in actinic keratosis (AK) under an IND from the FDA and is presently in a Phase 2a clinical trial in CTCL in Israel. The company’s strategic intellectual property portfolio covers broadly its general approach using the TopostericTM effect avoiding enzymatic cell mis-location.

For Further information about Vidac Pharma:
Max Herzberg, PhD. Active Chairman of the Board 
info@vidacpharma.com  
www.vidacpharma.com